Targeting IL-6 signaling via blocking the IL-6R and IL-6 with siRNA or mAbs resulted in reduced H460 cell (a cell line of human NSCLC) proliferation [16]. This evidence concerns the gene IL6 and non-small cell lung carcinoma.